Check 35,000+ stocks against 26 valuation models and 37 quality factors

Top Glove Corporation (TPGVF) fair value: what the stock is really worth

As of Sep 25, 2026: fair value of Top Glove Corporation $0.09, price $0.19, upside -52.6%, quality 62 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? No
Good quality? Yes
Add to watchlist

Healthcare · US · ISIN MYL7113OO003

Thin data Sep 24, 2026

Top Glove Corporation

TPGVF · US

Stretched ValuationStrong overvaluation with only moderate quality.

!Fair value $0.0900 · Strongly overvalued (−52.6%)

✓Quality 62/100

!Weak Growth (revenue 5y −13.6 %/yr)

!Thin margins · 4.8% net margin (TTM)

✓Low debt · generates free cash flow

!2.6% dividend yield · Payout strained

!Narrow moat 32/100

!Evidence only low, so the estimate is less certain

26 models, one by oneBear $0.0600 to bull $0.1100 Growth analysisrevenue history, year by year Quality 62/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch Top Glove Corporation for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range $0.0988 – $1.19 · fair‑value band $0.0600 – $0.1100 · the $0.1897 price screens above the $0.0900 fair value. Dashed = 300-day average. As of Sep 24, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Top Glove Corporation Bhd., an investment holding company, engages in the manufacture, trade, and sale of gloves in Malaysia, Thailand, the People's Republic of China, and internationally.

Top Glove Corporation Bhd., an investment holding company, engages in the manufacture, trade, and sale of gloves in Malaysia, Thailand, the People's Republic of China, and internationally. It offers nitrile, latex, surgical, rubber, examination, medical, and vinyl gloves; concentrate and synthetic latex, formers, chemicals and chemical compounds, rubber dental dams, exercise bands, condoms, and rubber related products; packaging materials, boxes, and cartons; and disposable and medical face masks, engineering parts and rubber glove machinery, functional fillers, healthcare products, and home care and personal care products. The company also provides property investment and consultancy services, and electrical engineering works; clinical and specialist medical services; analytical, medical related consultancy, emergency medical, advisory, accommodation, management and trading, and value added services; financial and treasury services; management services in plantation sector; processing of plantation produce; and industrial forest plantation services, as well as forestry and industry services. In addition, it trades in healthcare related products; distributes medical devices and products; operates as a special purpose vehicle solely for issuance of Perpetual Sukuk; organizes in-house trainings and public trainings/programs; and establishes and maintains fitness related business, including healthcare, slimming centers, gymnasiums, and other related activities. Further, it generates and supplies energy and electricity using biomass technology; and offers e-commerce services for glove trading and other healthcare products. Additionally, the company provides gamma irradiation services for sterilization of gloves and medical devices; acts as an agent in the sale of various goods; wholesales pharmaceutical goods; and buys and sells real estate. Top Glove Corporation Bhd. was founded in 1991 and is headquartered in Shah Alam, Malaysia.

Stock analysis

Top Glove Corporation (TPGVF) currently trades at $0.1897, while our model-based Fair Value estimate is $0.0900, 52.6% below the price, so the stock looks overvalued today.

Valuation

Bull case: the Asset-Based group reads highest at a median of $0.1000 per share, and 0 of the 26 models we run sit above the $0.1897 price.

Bear case: the Economic Profit group reads lowest at $0.0100, and 26 of the 26 models stay below the price. Evidence for this calculation is low.

Scenario range: $0.0600 (bear) to $0.1100 (bull), the price of $0.1897 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 62/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Top Glove Corporation reported revenue of 3.5B MYR in FY2025 versus 16.4B MYR in FY2021, a compound −32.0%/yr. Reported net income was 128M MYR in FY2025, compounding −64.1%/yr from FY2021.

Key figures

Market cap $1.5B · P/E ratio 19.0 · P/S ratio 0.70 · EPS (TTM) $0.0100 · Dividend yield 2.6% · Net margin 3.7% · Return on equity 3.8% · Return on assets (EBIT) 18.9%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 31 out of 100 (low confidence).

What moves the price

The share trades about 24% below its 52-week high and 92% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −37% fair-value upside, at −53%, TPGVF screens richer than that median.

Fair Value models

Bear $0.0600 Fair Value $0.0900 Bull $0.1100

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 12 months old). Earnings retained since then ($0.0050 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

FCF DCF $0.0600 $0.0900 $0.1200 81

Growth DCF $0.0600 $0.0800 $0.1100 79

Owner Earnings $0.1000 $0.1400 $0.2000 77

All 26 models by family

DCF Models

FCF DCF $0.0600 $0.0900 $0.1200 81

Owner Earnings $0.1000 $0.1400 $0.2000 77

5Y Revenue Exit $0.0300 $0.0400 $0.0500 74

5Y EBITDA Exit $0.0900 $0.1400 $0.2000 75

5Y P/E Exit $0.0600 $0.1000 $0.1300 71

10Y Revenue Exit $0.0400 $0.0500 $0.0600 68

10Y EBITDA Exit $0.0800 $0.1200 $0.1700 68

10Y P/E Exit $0.0600 $0.0900 $0.1200 64

Earnings-Based

Graham-Dodd $0.0300 $0.0900 $0.1200 65

Lynch FV $0.0200 $0.0300 $0.0400 61

PEG = 1.0 $0.0200 $0.0300 $0.0400 57

EPV $0.0100 $0.0100 $0.0200 70

Dividend Discount

Gordon GGM $0.0100 $0.0200 $0.0300 67

DDM Multi-Stage $0.0100 $0.0200 $0.0200 67

Multiples

P/E Multiple $0.0600 $0.0900 $0.1100 63

P/S Multiple $0.0500 $0.0700 $0.0800 58

P/B Multiple $0.0500 $0.0700 $0.0800 55

EV/EBIT $0.0200 $0.0200 $0.0200 66

EV/EBITDA $0.1100 $0.1500 $0.1800 67

EV/Revenue $0.0200 $0.0200 $0.0200 54

Asset-Based

NCAV (Graham) $0.0700 $0.1000 $0.1500 53

Growth DCF

Growth DCF $0.0600 $0.0800 $0.1100 79

Rev-Margin DCF $0.0300 $0.0400 $0.0500 74

Economic Profit

Residual Income $0.1000 $0.0900 $0.0900 76

ROIC Compounder $0.0100 $0.0100 $0.0200 69

Growth Earnings

Growth-Adj P/E $0.0500 $0.0800 $0.1000 67

Open the full fair value analysis →

Notify me when TPGVF reaches fair value

Put TPGVF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 62/100

Of which business quality 59 · Market factors (momentum, volatility) 53

Profitability 25

Margins and returns on capital today

Quality Growth 72

Are margins and returns improving?

Cashflow 51

Earnings quality: real cash, not paper profit

Fin. Strength 57

Balance sheet, leverage, solvency risk

Investment 96

Disciplined investing over empire-building

Low Volatility 50

Calm price path (market factor)

Momentum 51

Price trend over the last 3–12 months (market factor)

52W Momentum 57

Distance to the 52-week high (market factor)

Net Issuance 81

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 40/100

Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Revenue growth 1 year

+38.9%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

−14.4%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

−13.6%

Start year 2020 (pandemic)

Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+2.1%

’16

’17

’18

’19

’20

’21

’22

’23

’24

’25

Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.

29.7% (2020) → 0.6% (2025)

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2024 is a loss year, no rate is defined from a loss

not computed

Growth Forecast

A lot of optimism in the price

The price assumes more growth than the company has delivered so far and more than analysts expect.

What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).

+22.4%

Yearly growth needed for the next five years to justify today's price.

What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.

+11.9%

Yearly sales growth analysts expect, extended to five years.

After inflation (figures in MYR, Malaysia: IMF forecast 2.0% a year to 2030, 1.8% from 2016 to 2025) that is about +20.1% a year for the price and +9.7% for the forecasts.

Forecast 2026 (sales)+13.6%

Forecast 2027 (sales)+13.6%

Projected 2028 (sales)+12.2%

Projected 2029 (sales)+10.7%

Projected 2030 (sales)+9.3%

TPGVF screens overvalued: fair value 53% below the price. Compare with Intuitive Surgical, Inc →

Compare Top Glove Corporation with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 191 stocks

Beats the industry median on 10/14 measures

Overall it ranks above its industry peers.

Valuation

Quality Score 62 · Above median

Fair Value upside −54.3% · Bottom 25%

Profitability

Return on equity (TTM) 3.8% · Below median

Return on assets 1.4% · Below median

Net margin (TTM) 4.8% · Below median

Operating margin (TTM) 13.7% · Above median

Growth and dividend

Revenue growth 31.9% · Top 25%

Dividend yield (TTM) 2.6% · Above median

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/E (TTM) 19.0× · Cheaper than median

P/B 0.32× · Cheapest 25%

P/S (TTM) 0.40× · Cheapest 25%

P/FCF 9.5× · Cheapest 25%

EV/EBITDA 2.8× · Cheapest 25%

PEG 0.05× · Cheapest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Intuitive Surgical, Inc ISRG	$406.63	$348.72	−14%
EssilorLuxottica Société anonyme EL	€144.60	€159.06	+10%
Becton, Dickinson and Company BDX	$178.07	$104.73	−41%
Medline Inc MDLN	$34.70	$29.06	−16%
Alcon Inc ALC	$63.94	$40.13	−37%
West Pharmaceutical Services, Inc WST	$375.65	$137.81	−63%
Sartorius Stedim Biotech S.A DIM	€208.20	€54.82	−74%
Straumann Holding STMN	CHF 89.80	CHF 45.50	−49%
Sartorius Aktiengesellschaft SRT	€206.50	€42.05	−80%
Solventum Corporation SOLV	$89.50	$134.36	+50%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Top Glove Corporation · Fair Value
$0.0900 −53%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/TPGVF" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Top Glove Corporation · Fair Value</span><br><b style="font-size:20px">$0.0900</b> <span style="color:#e0816f;font-weight:700;font-size:14px">−53%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Top Glove Corporation Fair Value". https://www.fairvalue-calculator.com/stock/TPGVF

Frequently asked questions

Is Top Glove Corporation (TPGVF) overvalued or undervalued?

As of Sep 24, 2026, our model estimates a fair value of $0.0900 versus the last price from Sep 25, 2026 of $0.1897, about −53% upside (overvalued).

What is the fair value of TPGVF?

Our model-based fair value for Top Glove Corporation is $0.0900 (as of Sep 24, 2026), built from audited fundamentals. Last price (from Sep 25, 2026): $0.1897.

What is the quality score of TPGVF?

Top Glove Corporation has a Quality Score of 62/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Top Glove Corporation (TPGVF)?

Our model-based price target is the fair value of $0.0900 (as of Sep 24, 2026) from 26 valuation models. Cautious scenario $0.0600, optimistic scenario $0.1100. It is a calculation from audited fundamentals, not an analyst target.

What is the Top Glove Corporation stock forecast for 2026?

Our models put fair value at $0.0900, about −53% upside versus the last price from Sep 25, 2026 of $0.1897 (overvalued). Cautious scenario $0.0600, optimistic scenario $0.1100. The calculation is refreshed regularly with new filings.

What is the revenue of Top Glove Corporation (TPGVF)?

Top Glove Corporation reported trailing-twelve-month revenue of about 3.9B MYR (latest available figure, as of Sep 24, 2026).

Does Top Glove Corporation pay a dividend?

Top Glove Corporation currently shows a dividend yield of about 2.64% relative to its recent price (as of Sep 24, 2026).

What growth is priced into Top Glove Corporation (TPGVF)?

For today's price to be fair in a discounted-cash-flow model, Top Glove Corporation would have to grow free cash flow by +22.4 % per year for five years (discount rate 9.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -13.6 % per year. As of Sep 24, 2026.

What discount rate (WACC) does the fair value of TPGVF use?

Our models discount Top Glove Corporation at 9.8 %: a base by market capitalisation (small), damped by beta 0.45, country premium for USA. The same rate applies in all 26 models.

What is a reverse DCF?

A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Top Glove Corporation that is +22.4 % per year a year over ten years, using the same discount rate (9.8 %) and the same formula as our fair value.

How much growth has Top Glove Corporation (TPGVF) delivered so far?

Over the past 5 years revenue at Top Glove Corporation grew -13.6 % a year. The price currently implies +22.4 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.

How fast is the sector of Top Glove Corporation (TPGVF) growing?

The median revenue growth in the sector is +5.1 % a year. That is the yardstick for the growth priced into Top Glove Corporation (+22.4 % per year a year): it shows whether the expectation is within the usual range or beyond it.

What is the free cash flow yield of Top Glove Corporation (TPGVF)?

The free-cash-flow yield on the price is 2.61 %: that much free cash flow Top Glove Corporation produces per unit of market value. When it exceeds the discount rate of our models (9.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.

What is the intrinsic value of Top Glove Corporation (TPGVF)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Top Glove Corporation it is $0.0900 per share (as of Sep 24, 2026), against a price of $0.1897. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).

Is Top Glove Corporation stock overvalued or undervalued in 2026?

As of Sep 24, 2026, TPGVF trades above its calculated fair value: price $0.1897, fair value $0.0900, a gap of about −53% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of TPGVF?

No. The price is what the market pays today ($0.1897); the fair value is what the company's own numbers justify ($0.0900). For Top Glove Corporation the two are $0.0997 per share apart. That gap is exactly why we show both numbers side by side.

How much is Top Glove Corporation worth?

The market values Top Glove Corporation at about $1.5B (market capitalisation, as of Sep 24, 2026). Per share that is $0.1897; our models calculate a fair value of $0.0900 per share.

What do the bullish and bearish scenarios say about TPGVF?

Our models span a range for Top Glove Corporation: cautious scenario $0.0600, base $0.0900, optimistic $0.1100 per share (as of Sep 24, 2026, price $0.1897). The range comes from different growth and margin assumptions, not from analyst opinions.

What is the P/E ratio of TPGVF?

Top Glove Corporation trades at a price-to-earnings ratio of 19.0 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $0.0900 is built from several models across several years. Other multiples: PEG 0.0, P/B 0.3, P/S 0.4, EV/EBITDA 2.8.

What is the PEG ratio of TPGVF?

The PEG ratio of Top Glove Corporation is 0.05 (P/E divided by earnings growth, as of Sep 24, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.

How solid is the balance sheet of Top Glove Corporation (TPGVF)?

Balance-sheet figures for Top Glove Corporation (as of Sep 24, 2026): return on equity 3.8%. They feed the Quality Score of 62/100, which measures business quality independently of the share price.

How far is TPGVF from its 52-week high?

Top Glove Corporation trades at $0.1897, about 24% below its 52-week high of $0.2500 and 92% above the low of $0.0988 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0900 is for.

Which stocks are comparable to Top Glove Corporation?

From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Top Glove Corporation stock attractive at the current price?

The data as of Sep 24, 2026: price $0.1897, calculated fair value $0.0900 (−53%), Quality Score 62/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of TPGVF calculated?

We run Top Glove Corporation through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0900, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 14.5 % above its aggregate fair value. Top Glove Corporation itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Top Glove Corporation (TPGVF)?

The latest price we hold is from Sep 25, 2026 and stands at $0.1897. Our model-based fair value is $0.0900, about −53% upside (overvalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Top Glove Corporation right now?

The price sits above even our optimistic bull case ($0.1100). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (62/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($0.0600 to $0.1100) leaves room in how you read the outcome.

Key figures of Top Glove Corporation

How large is the market capitalisation of Top Glove Corporation (TPGVF)?

The market capitalisation of Top Glove Corporation is $1.5B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Top Glove Corporation (TPGVF)?

The price-to-sales ratio of Top Glove Corporation is 0.70 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of Top Glove Corporation (TPGVF)?

Earnings per share at Top Glove Corporation are $0.0100 (price ÷ EPS = P/E 19.0). Earnings per share over the last twelve months: total profit spread across every single share.

What is the dividend yield of Top Glove Corporation (TPGVF)?

The dividend yield of Top Glove Corporation is 2.6% (payout 50.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.

What is the net margin of Top Glove Corporation (TPGVF)?

The net margin of Top Glove Corporation is 3.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Top Glove Corporation (TPGVF)?

The return on equity (ROE) of Top Glove Corporation is 3.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Top Glove Corporation (TPGVF)?

On an EBIT basis the return on assets of Top Glove Corporation is 18.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Top Glove Corporation (TPGVF)?

The operating margin of Top Glove Corporation is 13.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Top Glove Corporation (TPGVF)?

Revenue at Top Glove Corporation is growing +31.9% versus a year earlier (3y avg −14.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at Top Glove Corporation (TPGVF)?

Earnings per share at Top Glove Corporation are growing +135% versus a year earlier. How much earnings per share grew versus a year earlier.

How much net debt does Top Glove Corporation (TPGVF) carry?

The net debt of Top Glove Corporation is 532M MYR (fiscal year 2025, ≈ 3.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.

Free · no account needed

Watch Top Glove Corporation in the live analysis

One click puts Top Glove Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.